FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4210367804> ?p ?o ?g. }

• W4210367804 abstract "Whilst the pharmacological profiles and mechanisms of antidepressants are varied, there are common reasons why they might help people to stop smoking tobacco. Firstly, nicotine withdrawal may produce depressive symptoms and antidepressants may relieve these. Additionally, some antidepressants may have a specific effect on neural pathways or receptors that underlie nicotine addiction.To assess the evidence for the efficacy, safety and tolerability of medications with antidepressant properties in assisting long-term tobacco smoking cessation in people who smoke cigarettes.We searched the Cochrane Tobacco Addiction Specialized Register, which includes reports of trials indexed in the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, and PsycINFO, clinicaltrials.gov, the ICTRP, and other reviews and meeting abstracts, in May 2019.We included randomized controlled trials (RCTs) that recruited smokers, and compared antidepressant medications with placebo or no treatment, an alternative pharmacotherapy, or the same medication used in a different way. We excluded trials with less than six months follow-up from efficacy analyses. We included trials with any follow-up length in safety analyses.We extracted data and assessed risk of bias using standard Cochrane methods. We also used GRADE to assess the certainty of the evidence. The primary outcome measure was smoking cessation after at least six months follow-up, expressed as a risk ratio (RR) and 95% confidence intervals (CIs). We used the most rigorous definition of abstinence available in each trial, and biochemically validated rates if available. Where appropriate, we performed meta-analysis using a fixed-effect model. Similarly, we presented incidence of safety and tolerance outcomes, including adverse events (AEs), serious adverse events (SAEs), psychiatric AEs, seizures, overdoses, suicide attempts, death by suicide, all-cause mortality, and trial dropout due to drug, as RRs (95% CIs).We included 115 studies (33 new to this update) in this review; most recruited adult participants from the community or from smoking cessation clinics. We judged 28 of the studies to be at high risk of bias; however, restricting analyses only to studies at low or unclear risk did not change clinical interpretation of the results. There was high-certainty evidence that bupropion increased long-term smoking cessation rates (RR 1.64, 95% CI 1.52 to 1.77; I2 = 15%; 45 studies, 17,866 participants). There was insufficient evidence to establish whether participants taking bupropion were more likely to report SAEs compared to those taking placebo. Results were imprecise and CIs encompassed no difference (RR 1.16, 95% CI 0.90 to 1.48; I2 = 0%; 21 studies, 10,625 participants; moderate-certainty evidence, downgraded one level due to imprecision). We found high-certainty evidence that use of bupropion resulted in more trial dropouts due to adverse events of the drug than placebo (RR 1.37, 95% CI 1.21 to 1.56; I2 = 19%; 25 studies, 12,340 participants). Participants randomized to bupropion were also more likely to report psychiatric AEs compared with those randomized to placebo (RR 1.25, 95% CI 1.15 to 1.37; I2 = 15%; 6 studies, 4439 participants). We also looked at the safety and efficacy of bupropion when combined with other non-antidepressant smoking cessation therapies. There was insufficient evidence to establish whether combination bupropion and nicotine replacement therapy (NRT) resulted in superior quit rates to NRT alone (RR 1.19, 95% CI 0.94 to 1.51; I2 = 52%; 12 studies, 3487 participants), or whether combination bupropion and varenicline resulted in superior quit rates to varenicline alone (RR 1.21, 95% CI 0.95 to 1.55; I2 = 15%; 3 studies, 1057 participants). We judged the certainty of evidence to be low and moderate, respectively; in both cases due to imprecision, and also due to inconsistency in the former. Safety data were sparse for these comparisons, making it difficult to draw clear conclusions. A meta-analysis of six studies provided evidence that bupropion resulted in inferior smoking cessation rates to varenicline (RR 0.71, 95% CI 0.64 to 0.79; I2 = 0%; 6 studies, 6286 participants), whilst there was no evidence of a difference in efficacy between bupropion and NRT (RR 0.99, 95% CI 0.91 to 1.09; I2 = 18%; 10 studies, 8230 participants). We also found some evidence that nortriptyline aided smoking cessation when compared with placebo (RR 2.03, 95% CI 1.48 to 2.78; I2 = 16%; 6 studies, 975 participants), whilst there was insufficient evidence to determine whether bupropion or nortriptyline were more effective when compared with one another (RR 1.30 (favouring bupropion), 95% CI 0.93 to 1.82; I2 = 0%; 3 studies, 417 participants). There was no evidence that any of the other antidepressants tested (including St John's Wort, selective serotonin reuptake inhibitors (SSRIs), monoamine oxidase inhibitors (MAOIs)) had a beneficial effect on smoking cessation. Findings were sparse and inconsistent as to whether antidepressants, primarily bupropion and nortriptyline, had a particular benefit for people with current or previous depression.There is high-certainty evidence that bupropion can aid long-term smoking cessation. However, bupropion also increases the number of adverse events, including psychiatric AEs, and there is high-certainty evidence that people taking bupropion are more likely to discontinue treatment compared with placebo. However, there is no clear evidence to suggest whether people taking bupropion experience more or fewer SAEs than those taking placebo (moderate certainty). Nortriptyline also appears to have a beneficial effect on smoking quit rates relative to placebo. Evidence suggests that bupropion may be as successful as NRT and nortriptyline in helping people to quit smoking, but that it is less effective than varenicline. There is insufficient evidence to determine whether the other antidepressants tested, such as SSRIs, aid smoking cessation, and when looking at safety and tolerance outcomes, in most cases, paucity of data made it difficult to draw conclusions. Due to the high-certainty evidence, further studies investigating the efficacy of bupropion versus placebo are unlikely to change our interpretation of the effect, providing no clear justification for pursuing bupropion for smoking cessation over front-line smoking cessation aids already available. However, it is important that where studies of antidepressants for smoking cessation are carried out they measure and report safety and tolerability clearly." @default.
• W4210367804 created "2022-02-08" @default.
• W4210367804 creator A5015470892 @default.
• W4210367804 creator A5062078849 @default.
• W4210367804 creator A5068967050 @default.
• W4210367804 creator A5085295770 @default.
• W4210367804 creator A5085681303 @default.
• W4210367804 date "2020-04-22" @default.
• W4210367804 modified "2023-10-09" @default.
• W4210367804 title "Antidepressants for smoking cessation" @default.
• W4210367804 cites W1064596239 @default.
• W4210367804 cites W136657926 @default.
• W4210367804 cites W145449476 @default.
• W4210367804 cites W1493174102 @default.
• W4210367804 cites W1495124014 @default.
• W4210367804 cites W1496088628 @default.
• W4210367804 cites W1499759686 @default.
• W4210367804 cites W1509407825 @default.
• W4210367804 cites W1522093184 @default.
• W4210367804 cites W1550538492 @default.
• W4210367804 cites W1561275855 @default.
• W4210367804 cites W1569162948 @default.
• W4210367804 cites W1585571950 @default.
• W4210367804 cites W1607776125 @default.
• W4210367804 cites W1685552966 @default.
• W4210367804 cites W1698788306 @default.
• W4210367804 cites W1709777073 @default.
• W4210367804 cites W171163379 @default.
• W4210367804 cites W1835789943 @default.
• W4210367804 cites W1859891561 @default.
• W4210367804 cites W1896061514 @default.
• W4210367804 cites W1912050742 @default.
• W4210367804 cites W1946428342 @default.
• W4210367804 cites W1951962722 @default.
• W4210367804 cites W1963492922 @default.
• W4210367804 cites W1963544765 @default.
• W4210367804 cites W1964076400 @default.
• W4210367804 cites W1964706595 @default.
• W4210367804 cites W1966933771 @default.
• W4210367804 cites W1967102337 @default.
• W4210367804 cites W1969859521 @default.
• W4210367804 cites W1969872550 @default.
• W4210367804 cites W1970537337 @default.
• W4210367804 cites W1971212397 @default.
• W4210367804 cites W1972641858 @default.
• W4210367804 cites W1974004281 @default.
• W4210367804 cites W1974058298 @default.
• W4210367804 cites W1974317576 @default.
• W4210367804 cites W1974335411 @default.
• W4210367804 cites W1974853174 @default.
• W4210367804 cites W1975936914 @default.
• W4210367804 cites W1976653331 @default.
• W4210367804 cites W1977850390 @default.
• W4210367804 cites W1979158851 @default.
• W4210367804 cites W1982279280 @default.
• W4210367804 cites W1982472985 @default.
• W4210367804 cites W1982554516 @default.
• W4210367804 cites W1983657379 @default.
• W4210367804 cites W1984780607 @default.
• W4210367804 cites W1984971527 @default.
• W4210367804 cites W1986181494 @default.
• W4210367804 cites W1986183173 @default.
• W4210367804 cites W1986563216 @default.
• W4210367804 cites W1986773132 @default.
• W4210367804 cites W1987721860 @default.
• W4210367804 cites W1987776021 @default.
• W4210367804 cites W1988102273 @default.
• W4210367804 cites W1990778593 @default.
• W4210367804 cites W1990984747 @default.
• W4210367804 cites W1992010621 @default.
• W4210367804 cites W1993820794 @default.
• W4210367804 cites W1993861075 @default.
• W4210367804 cites W1994093445 @default.
• W4210367804 cites W1994418475 @default.
• W4210367804 cites W1994470828 @default.
• W4210367804 cites W1994473494 @default.
• W4210367804 cites W1994905981 @default.
• W4210367804 cites W1995560501 @default.
• W4210367804 cites W1996352021 @default.
• W4210367804 cites W1996357191 @default.
• W4210367804 cites W1997073642 @default.
• W4210367804 cites W1999673711 @default.
• W4210367804 cites W2000039774 @default.
• W4210367804 cites W2001359769 @default.
• W4210367804 cites W2002314900 @default.
• W4210367804 cites W2002368082 @default.
• W4210367804 cites W2002850331 @default.
• W4210367804 cites W2004470066 @default.
• W4210367804 cites W2005501262 @default.
• W4210367804 cites W2006578141 @default.
• W4210367804 cites W2007262203 @default.
• W4210367804 cites W2008410508 @default.
• W4210367804 cites W2008817040 @default.
• W4210367804 cites W2009092564 @default.
• W4210367804 cites W2009310636 @default.
• W4210367804 cites W2009701287 @default.
• W4210367804 cites W2009875822 @default.
• W4210367804 cites W2010280912 @default.
• W4210367804 cites W2010397972 @default.
• W4210367804 cites W2010847301 @default.

• next